Superiority of high sensitivity cardiac troponin I over NT-proBNP and adiponectin for 7-year mortality in stable patients receiving haemodialysis
- PMID: 38769120
- PMCID: PMC11106234
- DOI: 10.1038/s41598-024-62491-4
Superiority of high sensitivity cardiac troponin I over NT-proBNP and adiponectin for 7-year mortality in stable patients receiving haemodialysis
Erratum in
-
Author Correction: Superiority of high sensitivity cardiac troponin I over NT‑proBNP and adiponectin for 7‑year mortality in stable patients receiving haemodialysis.Sci Rep. 2025 Feb 12;15(1):5232. doi: 10.1038/s41598-025-89201-y. Sci Rep. 2025. PMID: 39939691 Free PMC article. No abstract available.
Abstract
Patients on haemodialysis (HD) have high mortality risk, and prognostic values of the major cardiovascular biomarkers cardiac troponin I (cTnI), N-terminal pro-brain natriuretic peptide (NT-proBNP), and adiponectin should be ascertained over longer follow-up periods using higher-sensitivity assays, which we undertook. In 221 HD patients, levels of high-sensitivity (hs)-cTnI, NT-proBNP, and adiponectin, were measured using high-sensitivity assays, and their associations with all-cause mortality (ACM) and cardiovascular mortality (CVM) were prospectively investigated for 7 years. Higher hs-cTnI and NT-proBNP levels were significant risk factors for ACM and CVM in the Kaplan-Meier analysis. Multivariate Cox proportional hazards analyses in a model including hs-cTnI and NT-proBNP identified log hs-cTnI, but not log NT-proBNP, as an independent risk factor for ACM (HR 2.12, P < 0.02) and CVM (HR 4.48, P < 0.0005). Stepwise analyses identified a high hs-cTnI tertile as a risk factor for ACM (HR 2.31, P < 0.01) and CVM (HR 6.70, P < 0.001). The addition of hs-cTnI to a model including age, CRP, DM, and NT-proBNP significantly improved the discrimination of ACM and CVM each over 7 years. Conclusively, hs-cTnI was superior to NT-proBNP and adiponectin in predicting ACM and CVM over 7 years in HD patients, suggesting the significance of baseline hs-cTnI measurements in long-term management.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
References
-
- de Jager, D. J. et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA302, 1782–1789. 10.1001/jama.2009.1488 (2009). - PubMed
-
- Artunc, F. et al. Mortality prediction using modern peptide biomarkers in hemodialysis patients: A comparative analysis. Kidney Blood Pressure Res.39, 563–572. 10.1159/000368468 (2014). - PubMed
-
- Wang, A. Y. & Lai, K. N. Use of cardiac biomarkers in end-stage renal disease. J. Am. Soc. Nephrol. JASN19, 1643–1652. 10.1681/ASN.2008010012 (2008). - PubMed
-
- Khan, N. A., Hemmelgarn, B. R., Tonelli, M., Thompson, C. R. & Levin, A. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: A meta-analysis. Circulation112, 3088–3096. 10.1161/CIRCULATIONAHA.105.560128 (2005). - PubMed
-
- Ma, L. & Zhao, S. Risk factors for mortality in patients undergoing hemodialysis: A systematic review and meta-analysis. Int. J. Cardiol.238, 151–158. 10.1016/j.ijcard.2017.02.095 (2017). - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
